WallStSmart

CapsoVision, Inc. Common Stock (CV)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 36538% more annual revenue ($4.97B vs $13.56M). DXCM leads profitability with a 20.1% profit margin vs -198.9%. DXCM earns a higher WallStSmart Score of 72/100 (B).

CV

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -13.46

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 4.3Quality: 6.5
Piotroski: 5/9Altman Z: 2.67

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CV1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

Areas to Watch

CV4 concerns · Avg: 3.8/10
Price/BookValuation
16.6x4/10

Trading at 16.6x book value

Revenue GrowthGrowth
0.3%4/10

0.3% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$344.75M3/10

Smaller company, higher risk/reward

DXCM3 concerns · Avg: 4.0/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
33.0x4/10

Premium valuation, high expectations priced in

Price/BookValuation
13.2x4/10

Trading at 13.2x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CV

The strongest argument for CV centers on Debt/Equity.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : CV

The primary concerns for CV are Price/Book, Revenue Growth, EPS Growth.

Bear Case : DXCM

The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.

Key Dynamics to Monitor

CV profiles as a turnaround stock while DXCM is a mature play — different risk/reward profiles.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DXCM scores higher overall (72/100 vs 14/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CapsoVision, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.

Visit Website →

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?